For example, in the era of newer anti-HER2 therapies, such as in the phase II ATEMPT trial, although adjuvant trastuzumab emtansine (T-DM1) resulted in an excellent three-year invasive disease-free survival of 97.8%, this was not superior to paclitaxel/trastuzumab, and it did not reduce clinically relevant toxicity in patients with stage I HER2-positive breast cancer [24]. The gene discussed is ERBB2; the disease is breast carcinoma.